Effects of norepinephrine on the metabolism of fatty acids with different chain lengths in the perfused rat liver.
The effects of norepinephrine on ketogenesis in isolated hepatocytes have been reported as ranging from stimulation to inhibition. The present work was planned with the aim of clarifying these discrepancies. The experimental system was the once-through perfused liver from fasted and fed rats. Fatty acids with chain lengths varying from 8-18 were infused. The effects of norepinephrine depended on the metabolic state of the rat and on the nature of the fatty acid. Norepinephrine clearly inhibited ketogenesis from long-chain fatty acids (stearate > palmitate > oleate), but had little effect on ketogenesis from medium-chain fatty acids (octanoate and laureate). With palmitate the decrease in oxygen uptake was restricted to the substrate stimulated portion; with stearate, the decrease exceeded the substrate stimulated portion; with oleate, oxygen uptake was transiently inhibited. Withdrawal of Ca2+ attenuated the inhibitory effects. 14CO2 production from [1-14C]oleate was inhibited. Net uptake of the fatty acids was not affected by norepinephrine. In livers from fed rats, oxygen uptake and ketogenesis from stearate were only transiently inhibited. The conclusions are: (a) in the fasted state norepinephrine reduces ketogenesis and respiration by means of a Ca2+-dependent mechanism; (b) the degree of inhibition varies with the chain length and the degree of saturation of the fatty acids; (c) norepinephrine favours esterification of the activated long-chain fatty acids in detriment to oxidation; (d) in the fed state the stimulatory action of norepinephrine on glycogen catabolism induces conditions which are able to reverse inhibition of ketogenesis and oxygen uptake.
Ishii-Iwamoto
E L
EL
Department of Biochemistry, University of Maringá, Brazil.
Ferrarese
M L
ML
Constantin
J
J
Salgueiro-Pagadigorria
C
C
Bracht
A
A
D000090:Acetoacetates / Q000378:metabolism; D000818:Animals; D002245:Carbon Dioxide / Q000378:metabolism; D002333:Carnitine Acyltransferases / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005227:Fatty Acids / Q000378:metabolism* / Q000493:pharmacokinetics; D005508:Food Deprivation; D006885:Hydroxybutyrates / Q000378:metabolism; D007659:Ketones / Q000378:metabolism*; D008099:Liver / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology*; D008297:Male; D009638:Norepinephrine / Q000494:pharmacology*; D010100:Oxygen / Q000378:metabolism; D010477:Perfusion; D051381:Rats; D017208:Rats, Wistar; D012709:Serum Albumin / Q000494:pharmacology; D013228:Stearates / Q000494:pharmacology; D013997:Time Factors
D000090:Acetoacetates; D005227:Fatty Acids; D006885:Hydroxybutyrates; D007659:Ketones; D012709:Serum Albumin; D013228:Stearates; D002245:Carbon Dioxide; D002333:Carnitine Acyltransferases; D010100:Oxygen; D009638:Norepinephrine